Cell Therapeutics (CTIC) to Disclose Results from Phase I/II Trial of Non-Hodgkin's Lymphoma Treatment
Get Alerts CTIC Hot Sheet
Join SI Premium – FREE
Cell Therapeutics, Inc. (NASDAQ: CTIC) announced Monday that published results of a phase I/II clinical trial evaluating the effect of cyclophosphamide, pixantrone, vincristine, and prednisone in treating patients with aggressive non-Hodgkin's lymphoma will be included in the April 2011 edition of the peer reviewed journal, Leukemia & Lymphoma.
"Although there are a number of treatment regimens that have been studied as salvage therapies in patients with relapsed aggressive NHL, few have demonstrated a high proportion of complete responses and many of the remissions achieved are of relatively short duration," said Jack W. Singer, M.D. Chief Medical Officer at CTI.
A major tumor response was reported for 80% and 73% of patients in phase I and II respectively, with 57% and 47% of the patients achieving a complete or unconfirmed CR. Median overall survival in the phase II portion of the trial was 17.9 months with four patients achieving notable long-term disease-free survival ranging from 55 to 77 months, despite in some cases having failed multiple prior regimens including stem cell transplantation.
"Although there are a number of treatment regimens that have been studied as salvage therapies in patients with relapsed aggressive NHL, few have demonstrated a high proportion of complete responses and many of the remissions achieved are of relatively short duration," said Jack W. Singer, M.D. Chief Medical Officer at CTI.
A major tumor response was reported for 80% and 73% of patients in phase I and II respectively, with 57% and 47% of the patients achieving a complete or unconfirmed CR. Median overall survival in the phase II portion of the trial was 17.9 months with four patients achieving notable long-term disease-free survival ranging from 55 to 77 months, despite in some cases having failed multiple prior regimens including stem cell transplantation.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- QT Imaging (QTI) names Dr. Raluca Dinu as Acting Chief Executive Officer and Anastas Budagov as Chief Financial Officer
- Disney (DIS) Confirms Glass Lewis Recommends Shareholders Vote for Only its Director Nominees
- Daxor Corp. (DXR) CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!